Literature DB >> 2854948

Inhibitors of topoisomerase II: structure-activity relationships and mechanism of action of podophyllin congeners.

B H Long1, D A Stringfellow.   

Abstract

The specific inhibition of eukaryote DNA topoisomerase II by the anti-cancer drugs VP16, VM26, and 21 other congeners of podophyllotoxin has been extensively studied in this laboratory through the use of alkaline elution and other techniques. A structure-activity relationship has been established for cytotoxicity, single and double strand DNA breakage, and inhibition of the DNA strand passing activity of topoisomerase II. Furthermore, topoisomerase inhibition was measured in four naturally sensitive and resistant human lung carcinoma cells by quantifying the amount of single and double strand DNA breakage produced by VP16 and VM26 in cells and isolated nuclei. A direct correlation between double but not single strand DNA breaks and cytotoxicity was observed for the analogs in A549 human lung adenocarcinoma cells. In fact, some analogs were capable of producing substantial single strand DNA breakage without producing cytotoxicity. A similar correspondence was observed between double strand DNA breaks and cytotoxicity produced by VP16 and VM26 in the naturally sensitive and resistant cell lines. Evidence is also presented suggesting that the association of the drug with enzyme-DNA intermediate complex and the formation of the enzyme-DNA complex alone both reflected equilibrium governed conditions that were readily reversible. These studies support a model based on the proposal that the actual cytotoxic events are genetic alterations caused by possible heterologous subunit exchanges occurring between adjacent enzyme molecules, which result from the stabilization of the intermediate complex, rather than the actual loss of topoisomerase II activity caused by the inhibition. The resistance of normal cells and cells with acquired resistance to the possible clastogenic effects of topoisomerase inhibition may be, in part, related to the low topoisomerase II levels found in such cells. Topoisomerase II may also play a role in gene amplification and tumor cell heterogeneity by serving as a vehicle through which genetic recombination events may occur.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2854948     DOI: 10.1016/0065-2571(88)90019-2

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN: 0065-2571


  9 in total

1.  Incomplete reversion of double stranded DNA cleavage mediated by Drosophila topoisomerase II: formation of single stranded DNA cleavage complex in the presence of an anti-tumor drug VM26.

Authors:  M P Lee; T Hsieh
Journal:  Nucleic Acids Res       Date:  1992-10-11       Impact factor: 16.971

Review 2.  Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.

Authors:  Junko Murai; Anish Thomas; Markku Miettinen; Yves Pommier
Journal:  Pharmacol Ther       Date:  2019-05-23       Impact factor: 12.310

3.  Epstein-Barr virus induces fragmentation of chromosomal DNA during lytic infection.

Authors:  M Kawanishi
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

4.  Structure-activity relationships of VP-16 analogues.

Authors:  B H Long; A M Casazza
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.

Authors:  Yuko Maede; Hiroyasu Shimizu; Toru Fukushima; Toshiaki Kogame; Terukazu Nakamura; Tsuneharu Miki; Shunichi Takeda; Yves Pommier; Junko Murai
Journal:  Mol Cancer Ther       Date:  2013-10-15       Impact factor: 6.261

6.  Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines.

Authors:  G Toffoli; A Viel; L Tumiotto; G Biscontin; C Rossi; M Boiocchi
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

7.  bcl-2 gene enables rescue from in vitro myelosuppression (bone marrow cell death) induced by chemotherapy.

Authors:  S Kondo; D Yin; J Takeuchi; T Morimura; Y Oda; H Kikuchi
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

8.  Characterization of an etoposide-resistant human K562 cell line, K/eto.

Authors:  I Sugawara; T Iwahashi; K Okamoto; Y Sugimoto; H Ekimoto; T Tsuruo; T Ikeuchi; S Mori
Journal:  Jpn J Cancer Res       Date:  1991-09

Review 9.  Broken by the Cut: A Journey into the Role of Topoisomerase II in DNA Fragility.

Authors:  Naomi D Atkin; Heather M Raimer; Yuh-Hwa Wang
Journal:  Genes (Basel)       Date:  2019-10-12       Impact factor: 4.141

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.